Literature DB >> 9120258

Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex.

R H Carter1, G M Doody, J B Bolen, D T Fearon.   

Abstract

CD19 enhances membrane IgM (mIgM) signaling and is required for B lymphocyte responses to T-dependent Ags. CD19 is tyrosine phosphorylated when mIgM is ligated and binds SH2 domain-containing signaling proteins. We suggest that the basis for phosphorylation is the association of CD19 with Syk and other components of the mIgM complex. IgM, CD22, Ig-alpha, Ig-beta, and Syk were coimmunoprecipitated with CD19 from detergent lysates of B lymphocytes. The association was maintained with a chimeric form of CD19 containing only the transmembrane domain and the membrane proximal 17 amino acids of the cytoplasmic domain encoded by exon 6. This sequence is sufficient to mediate the association, as a synthetic peptide of the exon 6-encoded region adsorbs IgM and Syk. Deletion of the juxtamembrane 17 amino acids of the cytoplasmic domain encoded by CD19 exon 6 abolishes association of CD19 with the mIgM complex. Deletion of these amino acids, which contain no tyrosines, also reduces mIgM-induced tyrosine phosphorylation of the remainder of the CD19 cytoplasmic domain. Coligating this mutant CD19 to mIgM restores phosphorylation. Thus, a discrete region of the cytoplasmic domain regulates the tyrosine phosphorylation of CD19 in the activation of B cells by mIgM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120258

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  The role of complement in the acquired immune response.

Authors:  C H Nielsen; E M Fischer; R G Leslie
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

2.  CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

Authors:  Farrukh T Awan; Rosa Lapalombella; Rossana Trotta; Jonathan P Butchar; Bo Yu; Don M Benson; Julie M Roda; Carolyn Cheney; Xiaokui Mo; Amy Lehman; Jeffrey Jones; Joseph Flynn; David Jarjoura; John R Desjarlais; Susheela Tridandapani; Michael A Caligiuri; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2009-12-02       Impact factor: 22.113

3.  Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy.

Authors:  Cecille D Browne; Christopher J Del Nagro; Matthew H Cato; Hart S Dengler; Robert C Rickert
Journal:  Immunity       Date:  2009-11-05       Impact factor: 31.745

Review 4.  Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

Authors:  John C Allen; Fatima Talab; Joseph R Slupsky
Journal:  Int J Hematol Oncol       Date:  2016-05-26

5.  Visualization of negative signaling in B cells by quantitative confocal microscopy.

Authors:  H Phee; W Rodgers; K M Coggeshall
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 6.  CD19 function in central and peripheral B-cell development.

Authors:  Christopher J Del Nagro; Dennis C Otero; Amy N Anzelon; Sidne A Omori; Ravi V Kolla; Robert C Rickert
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell-positive selection.

Authors:  Laurent Verkoczy; Bao Duong; Patrick Skog; Djemel Aït-Azzouzene; Kamal Puri; José Luis Vela; David Nemazee
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

8.  MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures.

Authors:  Andrea Zangrando; Marta Campo Dell'orto; Geertruy Te Kronnie; Giuseppe Basso
Journal:  BMC Med Genomics       Date:  2009-06-23       Impact factor: 3.063

9.  The membrane skeleton controls diffusion dynamics and signaling through the B cell receptor.

Authors:  Bebhinn Treanor; David Depoil; Aitor Gonzalez-Granja; Patricia Barral; Michele Weber; Omer Dushek; Andreas Bruckbauer; Facundo D Batista
Journal:  Immunity       Date:  2010-02-18       Impact factor: 31.745

10.  A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL.

Authors:  Jennifer A Woyach; Farrukh Awan; Ian W Flinn; Jesus G Berdeja; Elizabeth Wiley; Sharmeen Mansoor; Ying Huang; Gerard Lozanski; Paul A Foster; John C Byrd
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.